Guidelines update, v35.1

Updates to the Australian guidelines for the clinical care of people with COVID-19 this week include:

• Tocilizumab – The references for REMAP-CAP and COVACTA (Rosas et al.) trials have been updated to reflect the published versions of the previously pre-print only articles – there was no change to the strength or direction of recommendation.

• Convalescent plasma – Text within the ‘summary’ section has been updated to reflect the identification of one new trial that is undergoing analysis (Salman et al. Egypt J Anaesth doi: 10.1080/11101849.2020.1842087).

• Zinc – Text within the ‘section text’ of zinc has been updated to reflect the identification of one new trial that is undergoing analysis (Patel et al. J Med Virol doi: 10.1002/jmv.26895).

• Ivermectin – Text has been added to the ‘Summary’ section of the evidence tab regarding the ineligibility of a previously identified trial for inclusion (Okumus et al), as assignment to the groups was not truly random.

Note: The newly identified studies listed above are currently under review and updated recommendations will be included in future versions of the guidelines.